-
Tadalafil, Eli Lillyâs blockbuster drug for erectile dysfunction, has now been approved to treat signs and symptoms of benign prostatic hyperplasia. Tadalafil is the first drug of its class to be approved for this indication.
-
-
From a large cohort of women followed prospectively and with an adjunct meta-analysis of existing evaluable studies, a clearly demonstrated, nearly universal (i.e., across tumor types) incremental increase in cancer incidence was observed with advancing height.
-
A newly developed instrument to measure brief physical activity counseling in primary care demonstrates that physicians need to do a better job.
-
Recent retrospective studies in Europe have created concern because of an observed increased risk of cancer (hazard ratio = 1.55) in users of insulin glargine (GLAR) compared to nonusers.
-
The authors conclude that patients with coronary stents undergoing an invasive procedure are at high risk of perioperative cardiovascular and bleeding complications, and that these are associated with a high mortality.
-
Good news: In a year when reports of financial downturns have dominated the headlines, results of the Contraceptive Technology Update 2011 Salary Survey reflect a holding pattern in salary levels.
-
The next file in your inbox is for a 35-year-old woman who has had recurrent vaginal infections. In the past year, she has had numerous episodes of itching, burning, and abnormal discharge.
-
Get ready for the latest presentations on evidence-based methods and practical tips for your practice at the two 2012 conferences for Contraceptive Technology.
-
In October 2011, Ohio became the seventh state to use new authority under the Affordable Care Act (ACA) to extend coverage for family planning services to women and men with incomes well above the state's standard Medicaid income eligibility ceilings.
